Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers

Category Primary study
JournalJournal of clinical oncology
Year 2017
This article has no abstract
Epistemonikos ID: 9b1cd164a36cf93a512f53911324dd9355d897d3
First added on: Feb 08, 2025